Contineum Therapeutics Statistics
Total Valuation
CTNM has a market cap or net worth of $106.07 million. The enterprise value is -$92.43 million.
Important Dates
The next estimated earnings date is Friday, May 16, 2025, before market open.
| Earnings Date | May 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CTNM has 25.87 million shares outstanding. The number of shares has increased by 469.95% in one year.
| Current Share Class | 19.14M |
| Shares Outstanding | 25.87M |
| Shares Change (YoY) | +469.95% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | 1.51% |
| Owned by Institutions (%) | 40.01% |
| Float | 13.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.54 |
| P/TBV Ratio | 0.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.69, with a Debt / Equity ratio of 0.03.
| Current Ratio | 20.69 |
| Quick Ratio | 20.53 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.19% and return on invested capital (ROIC) is -19.30%.
| Return on Equity (ROE) | -26.19% |
| Return on Assets (ROA) | -18.53% |
| Return on Invested Capital (ROIC) | -19.30% |
| Return on Capital Employed (ROCE) | -25.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.03M |
| Employee Count | 41 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -73.40% |
| 50-Day Moving Average | 6.07 |
| 200-Day Moving Average | 13.34 |
| Relative Strength Index (RSI) | 32.85 |
| Average Volume (20 Days) | 92,808 |
Short Selling Information
The latest short interest is 688,871, so 2.66% of the outstanding shares have been sold short.
| Short Interest | 688,871 |
| Short Previous Month | 689,245 |
| Short % of Shares Out | 2.66% |
| Short % of Float | 5.18% |
| Short Ratio (days to cover) | 12.55 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -50.89M |
| Pretax Income | n/a |
| Net Income | -42.26M |
| EBITDA | -50.64M |
| EBIT | -50.89M |
| Earnings Per Share (EPS) | -$2.18 |
Full Income StatementBalance Sheet
The company has $204.76 million in cash and $6.26 million in debt, giving a net cash position of $198.50 million or $7.67 per share.
| Cash & Cash Equivalents | 204.76M |
| Total Debt | 6.26M |
| Net Cash | 198.50M |
| Net Cash Per Share | $7.67 |
| Equity (Book Value) | 198.07M |
| Book Value Per Share | 7.66 |
| Working Capital | 196.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$32.85 million and capital expenditures -$514,000, giving a free cash flow of -$33.36 million.
| Operating Cash Flow | -32.85M |
| Capital Expenditures | -514,000 |
| Free Cash Flow | -33.36M |
| FCF Per Share | -$1.29 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |